Search Results - "Lentine, K.L."

The Changing Financial Landscape of Renal Transplant Practice: A National Cohort Analysis by Axelrod, D. A., Schnitzler, M. A., Xiao, H., Naik, A. S., Segev, D. L., Dharnidharka, V. R., Brennan, D. C., Lentine, K. L.

“…Kidney transplantation has become more resource intensive as recipient complexity has increased and average donor quality has diminished over time. A national…”
Get full text

A Retrospective Analysis of Immunosuppression Compliance, Dose Reduction and Discontinuation in Kidney Transplant Recipients by Takemoto, S. K., Pinsky, B. W., Schnitzler, M. A., Lentine, K. L., Willoughby, L. M., Burroughs, T. E., Bunnapradist, S.

“…We describe factors associated with poor compliance and dose reductions and examine the relative impact of compliance, dose reduction and discontinuation on…”
Get full text

The Clinical Importance of Flow Cytometry Crossmatch in the Context of CDC Crossmatch Results by Graff, R.J, Buchanan, P.M, Dzebisashvili, N, Schnitzler, M.A, Tuttle-Newhall, J, Xiao, H, Schadde, E, Gheorghian, A, Lentine, K.L

“…Abstract Background The complement-dependent microcytotoxicity crossmatch (CDCXM) is a standard method for evaluating the presence of preformed antibodies…”
Get full text

Patient and Graft Survival Implications of Simultaneous Pancreas Kidney Transplantation From Old Donors by Salvalaggio, P. R., Schnitzler, M. A., Abbott, K. C., Brennan, D. C., Irish, W., Takemoto, S. K., Axelrod, D., Santos, L. S., Kocak, B., Willoughby, L., Lentine, K. L.

“…We investigated graft and patient survival implications of simultaneous pancreas kidney (SPK) transplant from old donors. Data describing patients with type 1…”
Get full text

Variation in Comedication Use According to Kidney Transplant Immunosuppressive Regimens: Application of Integrated Registry and Pharmacy Claims Data by Lentine, K.L, Naik, A.S, Schnitzler, M, Axelrod, D, Chen, J, Brennan, D.C, Segev, D.L, Kasiske, B.L, Randall, H, Dharnidharka, V.R

“…Abstract Background Modern immunosuppression therapies (ISx) have many side effects, and transplant recipients must take an array of “comedications” to help…”
Get full text

OPTN/SRTR 2020 Annual Data Report: Kidney by Lentine, K. L., Smith, J. M., Hart, A., Miller, J., Skeans, M. A., Larkin, L., Robinson, A, Gauntt, K., Israni, A. K., Hirose, R., Snyder, J. J.

“…The year 2020 presented significant challenges to the field of kidney transplantation. After increasing each year since 2015 and reaching the highest annual…”
Get full text

OPTN/SRTR 2019 Annual Data Report: Kidney by Hart, A., Lentine, K. L., Smith, J. M., Miller, J. M., Skeans, M. A., Prentice, M., Robinson, A., Foutz, J., Booker, S. E., Israni, A. K., Hirose, R., Snyder, J. J.

“…Despite the ongoing severe shortage of available kidney grafts relative to candidates in need, data from 2019 reveal some promising trends. After remaining…”
Get full text

Perioperative Complications After Living Kidney Donation: A National Study by Lentine, K. L., Lam, N. N., Axelrod, D., Schnitzler, M. A., Garg, A. X., Xiao, H., Dzebisashvili, N., Schold, J. D., Brennan, D. C., Randall, H., King, E. A., Segev, D. L.

“…We integrated the US transplant registry with administrative records from an academic hospital consortium (97 centers, 2008–2012) to identify predonation…”
Get full text

Patterns of End‐Stage Renal Disease Caused by Diabetes, Hypertension, and Glomerulonephritis in Live Kidney Donors by Anjum, S., Muzaale, A. D., Massie, A. B., Bae, S., Luo, X., Grams, M. E., Lentine, K. L., Garg, A. X., Segev, D. L.

“…Inferences about late risk of end‐stage renal disease (ESRD) in live kidney donors have been extrapolated from studies averaging <10 years of follow‐up…”
Get full text

Transplant Outcomes and Economic Costs Associated with Patient Noncompliance to Immunosuppression by Pinsky, B. W., Takemoto, S. K., Lentine, K. L., Burroughs, T. E., Schnitzler, M. A., Salvalaggio, P. R.

“…We describe factors associated with immunosuppression compliance after kidney transplantation and examine relationships between compliance with allograft…”
Get full text

OPTN/SRTR 2020 Annual Data Report: Living Donor Collective by Kasiske, B L, Lentine, K L, Ahn, Y, Skeans, M A, Eberhard, T, Folken, C, Wainright, J, Larkin, L, Nystedt, C

“…The first successful solid organ transplant was a living donor kidney transplant in 1954. Since then, living donation has been an important source of organs…”
Get full text

The impact of direct‐acting antiviral agents on liver and kidney transplant costs and outcomes by Axelrod, D. A., Schnitzler, M. A., Alhamad, T., Gordon, F., Bloom, R. D., Hess, G. P., Xiao, H., Nazzal, M., Segev, D. L., Dharnidharka, V. R., Naik, A. S., Lam, N. N., Ouseph, R., Kasiske, B. L., Durand, C. M., Lentine, K. L.

“…Direct‐acting antiviral medications (DAAs) have revolutionized care for hepatitis C positive (HCV+) liver (LT) and kidney (KT) transplant recipients…”
Get full text

Prescription opioid use before and after kidney transplant: Implications for posttransplant outcomes by Lentine, K. L., Lam, N. N., Naik, A. S., Axelrod, D. A., Zhang, Z., Dharnidharka, V. R., Hess, G. P., Segev, D. L., Ouseph, R., Randall, H., Alhamad, T., Devraj, R., Gadi, R., Kasiske, B. L., Brennan, D. C., Schnitzler, M. A.

“…Evolving literature suggests that the epidemic of prescription opioid use affects the transplant population. We examined a novel database wherein national U.S…”
Get full text

The National Landscape of Living Kidney Donor Follow‐Up in the United States by Henderson, M. L., Thomas, A. G., Shaffer, A., Massie, A. B., Luo, X., Holscher, C. M., Purnell, T. S., Lentine, K. L., Segev, D. L.

“…In 2013, the Organ Procurement and Transplantation Network (OPTN)/ United Network for Organ Sharing (UNOS) mandated that transplant centers collect data on…”
Get full text

OPTN/SRTR 2016 Annual Data Report: Economics by Schnitzler, M. A., Skeans, M. A., Axelrod, D. A., Lentine, K. L., Randall, H. B., Snyder, J. J., Israni, A. K., Kasiske, B. L.

“…Medicare costs vary for solid organ transplant recipients by outcome: survival with graft function, survival with graft failure, and death. Average per‐person…”
Get full text

MELD Exceptions and Rates of Waiting List Outcomes by Massie, A. B., Caffo, B., Gentry, S. E., Hall, E. C., Axelrod, D. A., Lentine, K. L., Schnitzler, M. A., Gheorghian, A., Salvalaggio, P. R., Segev, D. L.

“…Model for End‐stage Liver Disease (MELD)‐based allocation of deceased donor livers allows exceptions for patients whose score may not reflect their true…”
Get full text

Addressing Geographic Disparities in Liver Transplantation Through Redistricting by Gentry, S. E., Massie, A. B., Cheek, S. W., Lentine, K. L., Chow, E. H., Wickliffe, C. E., Dzebashvili, N., Salvalaggio, P. R., Schnitzler, M. A., Axelrod, D. A., Segev, D. L.

“…Severe geographic disparities exist in liver transplantation; for patients with comparable disease severity, 90‐day transplant rates range from 18% to 86% and…”
Get full text

Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice by Dharnidharka, Vikas R, Naik, Abhijit S, Axelrod, David A, Schnitzler, Mark A, Zhang, Zidong, Bae, Sunjae, Segev, Dorry L, Brennan, Daniel C, Alhamad, Tarek, Ouseph, Rosemary, Lam, Ngan N, Nazzal, Mustafa, Randall, Henry, Kasiske, Bertram L, McAdams-Demarco, Mara, Lentine, Krista L

“…To assess factors that influence the choice of induction regimen in contemporary kidney transplantation, we examined center-identified, national transplant…”
Get more information

National Variation in Use of Immunosuppression for Kidney Transplantation: A Call for Evidence‐Based Regimen Selection by Axelrod, D. A., Naik, A. S., Schnitzler, M. A., Segev, D. L., Dharnidharka, V. R., Brennan, D. C., Bae, S., Chen, J., Massie, A., Lentine, K. L.

“…Immunosuppression management in kidney transplantation has evolved to include an increasingly diverse choice of medications. Although informed by patient and…”
Get full text

Estimated GFR for Living Kidney Donor Evaluation by Huang, N., Foster, M. C., Lentine, K. L., Garg, A. X., Poggio, E. D., Kasiske, B. L., Inker, L. A., Levey, A. S.

“…All living kidney donor candidates undergo evaluation of GFR. Guidelines recommend measured GFR (mGFR), using either an endogenous filtration marker or…”
Get full text